Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - Baxter Healthcare Pty Ltd, Mckinnon Direct Packaging & Fulfilment Pty Ltd, Advent Pharmaceuticals Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods available in Australia meet standards of quality, safety, and efficacy. This Act addresses the need for stringent regulation and oversight of the manufacture, supply, and advertising of therapeutic goods to protect public health. The Parliament of the Commonwealth of Australia established this legislative framework with the policy objective of safeguarding the health of Australians by controlling the therapeutic goods market effectively. The Act aims to maintain public confidence in the therapeutic goods available in the market by ensuring that only those goods that meet the prescribed standards are permitted for use. This legislative gazette from the Department of Health's Therapeutic Goods Administration serves as an official announcement of licences granted to specific companies for the manufacture of therapeutic goods, reinforcing the regulatory commitment to public health and safety.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Commonwealth of Australia, establishes a regulatory framework for therapeutic goods, including medicines, medical devices, blood, and tissues. The Act applies to various entities involved in the manufacture, supply, and importation of therapeutic goods within Australia. Specifically, it mandates licensing for entities engaged in the manufacture of therapeutic goods, ensuring that such activities meet prescribed quality and safety standards. The Act applies nationally across the Commonwealth, encompassing all states and territories within Australia, thereby establishing a uniform regulatory approach to the governance of therapeutic goods. Licences are granted under Section 38 of the Act to entities such as Baxter Healthcare Pty Ltd, McKinnon Direct Packaging & Fulfilment Pty Ltd, and Advent Pharmaceuticals Pty Ltd, as evidenced by the published list. The Act also delineates exclusions and exemptions, typically pertaining to certain low-risk goods or activities, which are further defined through subordinate instruments. The issuance of licences to specific entities signifies the TGA's commitment to overseeing the quality and safety of therapeutic goods available in the Australian market.

Key Provisions

The Therapeutic Goods Act 1989, under Section 38, empowers the Secretary to grant licences to entities for the manufacture of therapeutic goods. This provision is pivotal as it ensures that only approved and compliant entities can manufacture these goods, thereby safeguarding public health. The recent publication by Dr. Harry Rothenfluh, Delegate of the Secretary, lists Baxter Healthcare Pty Ltd, McKinnon Direct Packaging & Fulfilment Pty Ltd, and Advent Pharmaceuticals Pty Ltd as entities granted such licences. Each entity is identified by their respective licence numbers and addresses, marking the official recognition of their ability to manufacture therapeutic goods within Australia. Entities granted a licence under Section 38 of the Act must adhere to stringent regulatory standards. These standards encompass good manufacturing practices (GMP), quality control measures, and compliance with any other relevant legislative requirements. The licence holders are mandated to maintain comprehensive records of their manufacturing processes, ensuring traceability and accountability. Additionally, they must submit periodic reports to the Therapeutic Goods Administration (TGA) to demonstrate ongoing compliance. Failure to meet these obligations can result in the suspension or revocation of their licence, which would significantly impact their ability to operate in the therapeutic goods market. Breaching the obligations set forth in the Therapeutic Goods Act 1989 can lead to serious consequences. Section 33DA of the Act outlines various offences related to the unauthorised manufacture of therapeutic goods, which can attract both civil and criminal penalties. For instance, knowingly supplying therapeutic goods that do not comply with the Act can result in fines up to $2.75 million for corporations and lesser amounts for individuals, as per Section 33DB. Furthermore, individuals who are officers of a corporation and involved in the breach can face imprisonment for up to five years. These penalties underscore the importance of strict adherence to the Act's provisions and the severe repercussions of non-compliance.